Aura Biosciences (AURA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AURA Aura Biosciences

Watchlist

7.280
-0.090-1.22%

Close Feb 25 16:00 ET

7.280
0.0000.00%

Post 16:00 ET

363.65MMarket Cap-4.21P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

JMP Securities Maintains Aura Biosciences(AURA.US) With Buy Rating, Cuts Target Price to $21
Moomoo NewsFeb 20 11:31 ET · Ratings
Analysts Are Bullish on These Healthcare Stocks: Aura Biosciences Inc (AURA), Springworks Therapeutics (SWTX)
TipRanksFeb 20 10:50 ET · Ratings
Have Aura Biosciences Insiders Been Selling Stock?
Simply Wall StJan 24 05:01 ET
Insider Sale: See Remarks of $AURA (AURA) Sells 15,955 Shares
Quiver QuantitativeJan 21 21:15 ET
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket
BenzingaJan 3 05:11 ET
Buy Recommendation for Aura Biosciences Inc. Based on Promising Clinical Data and Growth Prospects
TipRanksDec 17, 2024 16:55 ET

Comments

PeterChen2

Dec 5, 2024 16:38

A lesson of collapse

$Aura Biosciences (AURA.US)$

Thatmyname

Oct 18, 2024 08:25

$Aura Biosciences (AURA.US)$ Thisssss

Trytosaveabit

Oct 17, 2024 15:10

News

$Aura Biosciences (AURA.US)$ Reuters· 1 min ago!
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-SAR in Patients With Non-Muscle-Invasive Bladder Cancer (Nmibc) in Ongoing Phase 1 Trial! No adverse events

Jaguar8

Sep 12, 2024 07:23

NEWS

$Aura Biosciences (AURA.US)$
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Aura Biosciences (NASDAQ: AURA) reported positive Phase 2 end of study results for bel-sar (AU-011) in treating early-stage choroidal melanoma (CM). The study showed an 80% tumor control rate and 90% visual acuity preservationamong Phase 3-eligible patients. Bel-sar demonstrated a highly favorable safety profile with no tre...